BioTime Presents New Data on OpRegen

BioTime shares were more than 2% higher in pre-market trading following the presentation of new data from the company’s phase I/IIa clinical trial of OpRegen for the treatment of advanced dry age-related macular degeneration. The results were presented Monday at the annual meeting of the Association for Research in Vision and Ophthalmology in Baltimore.

Imaging analysis suggests the transplanted OpRegen cells remained in place in an area of the scar that was completely depleted of retinal pigment epithelium because of the advanced stages of the disease. The data also continues to show that the procedure is well tolerated in all patients, including those patients with follow-up for more than one year after treatment. BioTime anticipates Data and Safety Monitoring Board review of cohort 2 by the end of tH2 2017 and if approved will then begin cohort 3 immediately after.